Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Regorafenib - Bayer Healthcare

Drug Profile

Regorafenib - Bayer Healthcare

Alternative Names: BAY-734506; fluoro-sorafenib; Resihance; Stivarga

Latest Information Update: 11 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare
  • Developer Bayer HealthCare; Bayer Zydus Pharma; British Columbia Cancer Agency; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; Ono Pharmaceutical; Spanish Cooperative Group for Digestive Tumour Therapy; University of Pittsburgh
  • Class Amides; Antineoplastics; Eye disorder therapies; Fluorobenzenes; Phenylurea compounds; Pyridines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Bcr-Abl tyrosine kinase modulators; EphA2 receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Raf kinase inhibitors; Receptor protein-tyrosine kinase antagonists; TIE 2 receptor antagonists; TrkA receptor antagonists; Type 1 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Gastrointestinal stromal tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Gastrointestinal stromal tumours; Liver cancer
  • Phase II Adenoid cystic carcinoma; Biliary cancer; Cholangiocarcinoma; Glioblastoma; Pancreatic cancer; Renal cell carcinoma; Solid tumours
  • Phase I Acute myeloid leukaemia
  • Preclinical Rhabdomyosarcoma
  • Discontinued Non-small cell lung cancer; Wet age-related macular degeneration

Most Recent Events

  • 16 Jan 2019 Bayer Oncology in collaboration with Global Coalition for Adaptive Research plans a clinical trial for Glioblastoma (First-line therapy, Recurrent) in the United States, Canada, and Australia Europe and Asia in early 2019
  • 07 Jan 2019 National Cancer Center and Bayer completes a phase II trial in Gastrointestinal stromal tumors (Second line therapy or greater, Metastatic disease, Inoperable/Unresectable) (PO) (UMIN000016115)
  • 14 Nov 2018 Bayer and The Global Coalition for Adaptive Research enter into a agreement for a clinical trial of Glioblastoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top